STOCK TITAN

Attovia Therapeutics (ATTO) CSO reports common stock and multi-year option grants

(Neutral)
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. lists initial equity holdings for Chief Scientific Officer Petter Veiby. He directly holds 104,951 shares of Common Stock. He also holds four stock option awards over Common Stock: 5,382 shares at an exercise price of $2.8799 expiring March 5, 2034; 107,642 shares at $3.5302 expiring May 8, 2034; 89,343 shares at $4.9237 expiring May 17, 2035; and 18,837 shares at $1.5793 expiring August 16, 2033. Each option vests over four years, with 25% vesting on specified initial dates in 2024–2026 and the remaining 75% vesting in equal monthly installments over three years, subject to continued service.

Positive

  • None.

Negative

  • None.
Insider Veiby Petter
Role Chief Scientific Officer
Type Security Shares Price Value
holding Stock Option (Right to Buy) F1 -- -- --
holding Stock Option (Right to Buy) F2 -- -- --
holding Stock Option (Right to Buy) F3 -- -- --
holding Stock Option (Right to Buy) F4 -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 221,204 shares (Direct); Common Stock — 104,951 shares (Direct)
Footnotes (4)
  1. F1. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on March 6, 2025, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.
  2. F2. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on May 9, 2025, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.
  3. F3. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on May 18, 2026, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.
  4. F4. The options vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on June 19, 2024, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.
Direct Common Stock Holdings 104,951 shares Common Stock directly owned by Petter Veiby as reported
Option Exercise Price $2.8799 Stock Option (Right to Buy) expiring March 5, 2034; 5,382 underlying shares
Underlying Shares at $2.8799 5,382 shares Underlying Common Stock for option expiring March 5, 2034
Option Exercise Price $3.5302 Stock Option (Right to Buy) expiring May 8, 2034; 107,642 underlying shares
Underlying Shares at $3.5302 107,642 shares Underlying Common Stock for option expiring May 8, 2034
Option Exercise Price $4.9237 Stock Option (Right to Buy) expiring May 17, 2035; 89,343 underlying shares
Option Exercise Price $1.5793 Stock Option (Right to Buy) expiring August 16, 2033; 18,837 underlying shares
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
underlying security financial
"underlying_security_title: Common Stock"
vesting schedule financial
"The vesting schedule is as follows: 25% of the shares..."
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
exercise price financial
"conversion_or_exercise_price: 4.9237"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity stake does Petter Veiby report in Attovia Therapeutics (ATTO)?

Petter Veiby reports direct ownership of 104,951 shares of Common Stock in Attovia Therapeutics, Inc. He also holds several stock options covering additional shares of Common Stock at various exercise prices and expiration dates.

What stock options does Petter Veiby hold in Attovia Therapeutics (ATTO)?

He holds four stock option positions over Common Stock: 5,382 shares at $2.8799, 107,642 shares at $3.5302, 89,343 shares at $4.9237, and 18,837 shares at $1.5793, each with different expiration dates through 2035.

How do Petter Veiby’s stock options in ATTO vest over time?

Each option vests over a four-year period. 25% of the underlying shares vested on specified dates in 2024–2026, and the remaining 75% vest in 1/48th monthly installments over three years, subject to continued service.

When do Petter Veiby’s Attovia Therapeutics (ATTO) options expire?

The reported options expire on August 16, 2033, March 5, 2034, May 8, 2034, and May 17, 2035, respectively. Each grant has its own exercise price and underlying share amount tied to these expiration dates.

Are there buy or sell transactions reported for Petter Veiby’s ATTO holdings?

The filing lists holdings of Common Stock and stock options for Petter Veiby but does not report any buy or sell transactions. It reflects his positions rather than recent trading activity.

What conditions apply to vesting of Petter Veiby’s ATTO stock options?

Vesting is subject to continued service with Attovia Therapeutics. After an initial 25% vesting on specified dates, the remaining shares vest in equal monthly installments over three years, conditioned on ongoing service to the issuer.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Veiby Petter

(Last)(First)(Middle)
C/O ATTOVIA THERAPEUTICS, INC.
1091 INDUSTRIAL ROAD, SUITE 310

(Street)
SAN CARLOS CALIFORNIA 94070

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2026
3. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock104,951D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (1)03/05/2034Common Stock5,382$2.8799D
Stock Option (Right to Buy) (2)05/08/2034Common Stock107,642$3.5302D
Stock Option (Right to Buy) (3)05/17/2035Common Stock89,343$4.9237D
Stock Option (Right to Buy) (4)08/16/2033Common Stock18,837$1.5793D
Explanation of Responses:
1. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on March 6, 2025, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.
2. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on May 9, 2025, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.
3. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on May 18, 2026, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.
4. The options vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on June 19, 2024, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.
/s/ Steven Chan, Attorney-in-Fact08/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)